- Home
- SHFS vs VYNE Comparison
SHFS vs VYNE Comparison
Compare SHFS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- VYNE
- Stock Information
- Founded
- SHFS 2015
- VYNE 2003
- Country
- SHFS United States
- VYNE United States
- Employees
- SHFS N/A
- VYNE N/A
- Industry
- SHFS Finance: Consumer Services
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SHFS Finance
- VYNE Health Care
- Exchange
- SHFS Nasdaq
- VYNE Nasdaq
- Market Cap
- SHFS 35.0M
- VYNE 38.2M
- IPO Year
- SHFS N/A
- VYNE 2018
- Fundamental
- Price
- SHFS $0.59
- VYNE $1.90
- Analyst Decision
- SHFS
- VYNE Strong Buy
- Analyst Count
- SHFS 0
- VYNE 1
- Target Price
- SHFS N/A
- VYNE $5.75
- AVG Volume (30 Days)
- SHFS 39.9K
- VYNE 40.5K
- Earning Date
- SHFS 08-14-2024
- VYNE 08-14-2024
- Dividend Yield
- SHFS N/A
- VYNE N/A
- EPS Growth
- SHFS N/A
- VYNE N/A
- EPS
- SHFS 0.08
- VYNE N/A
- Revenue
- SHFS $16,719,536.00
- VYNE $486,000.00
- Revenue This Year
- SHFS N/A
- VYNE $32.31
- Revenue Next Year
- SHFS N/A
- VYNE N/A
- P/E Ratio
- SHFS $6.98
- VYNE N/A
- Revenue Growth
- SHFS 34.73
- VYNE 19.41
- 52 Week Low
- SHFS $0.41
- VYNE $1.57
- 52 Week High
- SHFS $1.55
- VYNE $4.48
- Technical
- Relative Strength Index (RSI)
- SHFS 45.96
- VYNE 53.49
- Support Level
- SHFS $0.55
- VYNE $1.77
- Resistance Level
- SHFS $0.65
- VYNE $1.98
- Average True Range (ATR)
- SHFS 0.05
- VYNE 0.10
- MACD
- SHFS -0.01
- VYNE 0.02
- Stochastic Oscillator
- SHFS 40.00
- VYNE 51.61
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.